论文部分内容阅读
目的探讨雷贝拉唑(江苏豪森医药集团)、莫沙比利治疗胃食管反流病的临床疗效。方法将124例确诊为反流性食管炎的患者随机分为2组,治疗组(62例)给予雷贝拉唑(10mg,2次/d)联合莫沙比利(5mg,3次/d)治疗;对照组(62例)给予奥美拉唑(阿斯利康有限公司)20mg,2次/d联合多潘立酮(10mg,3次/d)治疗,观察其临床疗效。结果治疗组和对照组分别在症状和胃镜下疗效方面差异有统计学意义(P<0.05)。结论雷贝拉唑联合莫沙比例治疗胃食管反流病优于奥美拉唑联合多潘立酮。
Objective To investigate the clinical efficacy of rabeprazole (Jiangsu Howson Pharmaceutical Group) and mosapride in the treatment of gastroesophageal reflux disease. Methods A total of 124 patients with reflux esophagitis were randomly divided into two groups. The treatment group (62 cases) received rabeprazole (10 mg twice daily) combined with mosapride (5 mg three times daily ). The control group (62 cases) was given omeprazole (AstraZeneca Co., Ltd.) 20mg, 2 times / d combined with domperidone (10mg, 3 times / d) treatment, observe its clinical efficacy. Results There were significant differences between the treatment group and the control group in symptom and endoscopy efficacy (P <0.05). Conclusion Rabeprazole combined with mosapride in the treatment of gastroesophageal reflux disease is superior to omeprazole combined with domperidone.